China National Accord Medicines Corp Ltd
SZSE:000028
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
CN |
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
21.5B CNY | 16 | |
US |
Mckesson Corp
NYSE:MCK
|
72.5B USD | 20.3 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 21.9 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 13.7 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.6B USD | 12.2 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 24.9 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -285 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 3.1 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.5B EUR | 31.4 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 28.2 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | -94 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.